Skip to main content

Table 3 Severity of reaction by modified NCI scale

From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis

Grade 1A

Cutaneous rash, flushing, generalised pruritus

5 (17.9%)

Grade 1B

1A plus, back pain and or HTN

2 (7.1%)

Grade 2

Urticaria, nausea/vomiting, throat tightness, Asymptomatic bronchospasm, chest tightness

3 (10.7%)

Grade 3

Symptomatic bronchospasm, dysponea, hypoxia, wheeze

7 (25%)

Grade 4

Anaphylaxis, hypotension

0

Grade 5

Death

1 (3.6%)

Unclassified

due to lack of information available to stratify severity

4 (14.3%)

Delayed

adverse event occurred after 48 h of infusion

6 (21.4%)